BI partners two of its antibody candidates with AbbVie
Boehringer Ingelheim GMBH is partnering with AbbVie Inc. on two clinical-stage antibody therapies--anti-IL-23 BI655066 and anti-CD-40 BI655064.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com